Stock Events

Stock Events

Perspective Therapeutics 

$3.12
95
+$0.02+0.65% Thursday 20:00
+$0.02+0.72%Thursday 23:30After hours

Statistics

Day High
3.12
Day Low
3.1
52W High
6.16
52W Low
1.96
Volume
50,911
Avg. Volume
-
Mkt Cap
356.15M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.57
-0.45
-0.34
-0.22
Expected EPS
-0.240554
Actual EPS
N/A

Financials

-11,665.27%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
884,000Revenue
-103.12MNet Income

Analyst Ratings

11.13Average Price Target
The highest estimate is 14.00.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CATX. It's not an investment recommendation.
NVIDIA
15
NVDA
Palantir Technologies
13
PLTR
Strategy
13
MSTR
Apple
12
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap292.35B
Novartis operates in the oncology segment, directly competing with Perspective Therapeutics' cancer-focused therapies.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio of oncology drugs, making it a key competitor in the cancer treatment market.
Merck
MRK
Mkt Cap366B
Merck is known for its strong presence in the cancer drug market, especially with its blockbuster drug Keytruda.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb offers a wide range of cancer treatments, competing in the same space as Perspective Therapeutics.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG, through its Genentech division, is a leading company in cancer therapeutics, directly competing with Perspective Therapeutics.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a significant oncology portfolio, including treatments for various types of cancer.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, with its acquisitions and development in oncology, is a competitor in the cancer treatment market.
AMGEN
AMGN
Mkt Cap233.78B
Amgen has a growing focus on oncology, with several cancer drugs in its portfolio.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen Pharmaceutical Companies, offers cancer treatments, competing in the oncology sector.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, known for its innovative treatments, is expanding its oncology portfolio, making it a competitor.

About

Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Show more...
CEO
Johan Spoor
Employees
166
Country
United States
ISIN
US46489V3024
WKN
000A40EDR

Listings

STU
DE
AAJ0.STU
F
DE
AAJ0.F
MU
DE
AAJ0.MU
XASE
US
CATX

0 Comments

Share your thoughts

FAQ

What is Perspective Therapeutics stock price today?▼
The current price of CATX is $3.12 USD — it has increased by +0.65% in the past 24 hours. Watch Perspective Therapeutics stock price performance more closely on the chart.
What is Perspective Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XASE exchange Perspective Therapeutics stocks are traded under the ticker CATX.
Is Perspective Therapeutics stock price growing?▼
CATX stock has risen by +0.32% compared to the previous week, the month change is a +4% rise, over the last year Perspective Therapeutics has showed a -11.86% decrease.
What is Perspective Therapeutics market cap?▼
Today Perspective Therapeutics has the market capitalization of 356.15M
When is the next Perspective Therapeutics earnings date?▼
Perspective Therapeutics is going to release the next earnings report on November 17, 2026.
What were Perspective Therapeutics earnings last quarter?▼
CATX earnings for the last quarter are -0.22 USD per share, whereas the estimation was -0.25 USD resulting in a +12.38% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Perspective Therapeutics revenue for the last year?▼
Perspective Therapeutics revenue for the last year amounts to 884,000 USD.
What is Perspective Therapeutics net income for the last year?▼
CATX net income for the last year is -103.12M USD.
How many employees does Perspective Therapeutics have?▼
As of September 04, 2026, the company has 166 employees.
In which sector is Perspective Therapeutics located?▼
Perspective Therapeutics operates in the Health & Wellness sector.
When did Perspective Therapeutics complete a stock split?▼
The last stock split for Perspective Therapeutics was on June 17, 2024 with a ratio of 1:10.
Where is Perspective Therapeutics headquartered?▼
Perspective Therapeutics is headquartered in SEATTLE, United States.